aTYR PHARMA (ATYR) Treasury Shares (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Treasury Shares came in at $409404.0 in Q1 2026, up 1936.03% YoY from $20108.0 in Q1 2025, and up 1936.03% on a QoQ basis from $20108.0 in Q4 2025.
aTYR PHARMA (ATYR) Treasury Shares (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Treasury Shares data on file, last reported at $409404.0 in Q1 2026.
- Quarterly Treasury Shares rose 1936.03% year-over-year to $409404.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $409404.0 (up 1936.03% YoY) and the FY2025 annual result came in at $20108.0, down 51.21% from the prior year.
- Treasury Shares rose to $409404.0 in Q1 2026, from $20108.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $409404.0 in Q1 2026 to a low of $20108.0 in Q1 2025.
- A 5-year average of $81985.9 and a median of $63327.0 in 2023 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2024 — Treasury Shares plunged 58.5% — and 2026, when it surged 1936.03%.
- Tracing ATYR's Treasury Shares over 5 years: stood at $121438.0 in 2022, then plunged by 47.85% to $63327.0 in 2023, then tumbled by 34.92% to $41216.0 in 2024, then tumbled by 51.21% to $20108.0 in 2025, then surged by 1936.03% to $409404.0 in 2026.
- The last three Treasury Shares figures came in at $409404.0 (Q1 2026), $20108.0 (Q4 2025), and $20108.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407,217.00 |
| Jun 30, 2026 | 407,217.00 |
| Mar 31, 2026 | 409,404.00 |
| Mar 31, 2026 | 409,404.00 |
| Dec 31, 2025 | 20,108.00 |
| Dec 31, 2025 | 20,108.00 |
| Sep 30, 2025 | 20,108.00 |
| Sep 30, 2025 | 20,108.00 |
| Jun 30, 2025 | 20,108.00 |
| Jun 30, 2025 | 20,108.00 |
| Mar 31, 2025 | 20,108.00 |
| Mar 31, 2025 | 20,108.00 |
| Dec 31, 2024 | 41,216.00 |
| Dec 31, 2024 | 41,216.00 |
| Sep 30, 2024 | 41,216.00 |
| Sep 30, 2024 | 41,216.00 |
| Jun 30, 2024 | 41,216.00 |
| Jun 30, 2024 | 41,216.00 |
| Mar 31, 2024 | 41,216.00 |
| Mar 31, 2024 | 41,216.00 |